A combined tissue-engineered/in silico signature tool patient stratification in lung cancer

Patient-tailored therapy based on tumor drivers is promising for lung cancer treatment. For this, we combined in vitro tissue models with in silico analyses. Using individual cell lines with specific mutations, we demonstrate a generic and rapid stratification pipeline for targeted tumor therapy. We...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Göttlich, Claudia (VerfasserIn) , Kunz, Meik (VerfasserIn) , Zapp, Cornelia (VerfasserIn) , Nietzer, Sarah L. (VerfasserIn) , Walles, Heike (VerfasserIn) , Dandekar, Thomas (VerfasserIn) , Dandekar, Gudrun (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 24 May 2018
In: Molecular oncology
Year: 2018, Jahrgang: 12, Heft: 8, Pages: 1264-1285
ISSN:1878-0261
DOI:10.1002/1878-0261.12323
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1002/1878-0261.12323
Verlag, lizenzpflichtig, Volltext: https://febs.onlinelibrary.wiley.com/doi/abs/10.1002/1878-0261.12323
Volltext
Verfasserangaben:Claudia Göttlich, Meik Kunz, Cornelia Zapp, Sarah L. Nietzer, Heike Walles, Thomas Dandekar and Gudrun Dandekar

MARC

LEADER 00000caa a2200000 c 4500
001 1696293588
003 DE-627
005 20230426182343.0
007 cr uuu---uuuuu
008 200428s2018 xx |||||o 00| ||eng c
024 7 |a 10.1002/1878-0261.12323  |2 doi 
035 |a (DE-627)1696293588 
035 |a (DE-599)KXP1696293588 
035 |a (OCoLC)1341316943 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 32  |2 sdnb 
100 1 |a Göttlich, Claudia  |e VerfasserIn  |0 (DE-588)1190605899  |0 (DE-627)1669183572  |4 aut 
245 1 2 |a A combined tissue-engineered/in silico signature tool patient stratification in lung cancer  |c Claudia Göttlich, Meik Kunz, Cornelia Zapp, Sarah L. Nietzer, Heike Walles, Thomas Dandekar and Gudrun Dandekar 
264 1 |c 24 May 2018 
300 |a 22 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 28.04.2020 
520 |a Patient-tailored therapy based on tumor drivers is promising for lung cancer treatment. For this, we combined in vitro tissue models with in silico analyses. Using individual cell lines with specific mutations, we demonstrate a generic and rapid stratification pipeline for targeted tumor therapy. We improve in vitro models of tissue conditions by a biological matrix-based three-dimensional (3D) tissue culture that allows in vitro drug testing: It correctly shows a strong drug response upon gefitinib (Gef) treatment in a cell line harboring an EGFR-activating mutation (HCC827), but no clear drug response upon treatment with the HSP90 inhibitor 17AAG in two cell lines with KRAS mutations (H441, A549). In contrast, 2D testing implies wrongly KRAS as a biomarker for HSP90 inhibitor treatment, although this fails in clinical studies. Signaling analysis by phospho-arrays showed similar effects of EGFR inhibition by Gef in HCC827 cells, under both 2D and 3D conditions. Western blot analysis confirmed that for 3D conditions, HSP90 inhibitor treatment implies different p53 regulation and decreased MET inhibition in HCC827 and H441 cells. Using in vitro data (western, phospho-kinase array, proliferation, and apoptosis), we generated cell line-specific in silico topologies and condition-specific (2D, 3D) simulations of signaling correctly mirroring in vitro treatment responses. Networks predict drug targets considering key interactions and individual cell line mutations using the Human Protein Reference Database and the COSMIC database. A signature of potential biomarkers and matching drugs improve stratification and treatment in KRAS-mutated tumors. In silico screening and dynamic simulation of drug actions resulted in individual therapeutic suggestions, that is, targeting HIF1A in H441 and LKB1 in A549 cells. In conclusion, our in vitro tumor tissue model combined with an in silico tool improves drug effect prediction and patient stratification. Our tool is used in our comprehensive cancer center and is made now publicly available for targeted therapy decisions. 
650 4 |a 3D lung tumor model 
650 4 |a Boolean signaling network 
650 4 |a chemoresistance 
650 4 |a HSP90 inhibitor 
650 4 |a in silico drug screening tool 
650 4 |a KRAS mutation signature 
700 1 |a Kunz, Meik  |e VerfasserIn  |4 aut 
700 1 |a Zapp, Cornelia  |d 1991-  |e VerfasserIn  |0 (DE-588)1206290994  |0 (DE-627)1692282271  |4 aut 
700 1 |a Nietzer, Sarah L.  |e VerfasserIn  |4 aut 
700 1 |a Walles, Heike  |e VerfasserIn  |4 aut 
700 1 |a Dandekar, Thomas  |d 1960-  |e VerfasserIn  |0 (DE-588)120961059  |0 (DE-627)080996604  |0 (DE-576)166308323  |4 aut 
700 1 |a Dandekar, Gudrun  |d 1971-  |e VerfasserIn  |0 (DE-588)128932902  |0 (DE-627)385678940  |0 (DE-576)297405985  |4 aut 
773 0 8 |i Enthalten in  |t Molecular oncology  |d Hoboken, NJ : John Wiley & Sons, Inc., 2007  |g 12(2018), 8, Seite 1264-1285  |h Online-Ressource  |w (DE-627)531199800  |w (DE-600)2322586-5  |w (DE-576)271586621  |x 1878-0261  |7 nnas  |a A combined tissue-engineered/in silico signature tool patient stratification in lung cancer 
773 1 8 |g volume:12  |g year:2018  |g number:8  |g pages:1264-1285  |g extent:22  |a A combined tissue-engineered/in silico signature tool patient stratification in lung cancer 
856 4 0 |u https://doi.org/10.1002/1878-0261.12323  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://febs.onlinelibrary.wiley.com/doi/abs/10.1002/1878-0261.12323  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20200428 
993 |a Article 
994 |a 2018 
998 |g 1206290994  |a Zapp, Cornelia  |m 1206290994:Zapp, Cornelia  |d 140000  |e 140000PZ1206290994  |k 0/140000/  |p 3 
999 |a KXP-PPN1696293588  |e 3639510046 
BIB |a Y 
SER |a journal 
JSO |a {"physDesc":[{"extent":"22 S."}],"relHost":[{"origin":[{"publisherPlace":"Hoboken, NJ ; Amsterdam [u.a.]","dateIssuedDisp":"2007-","publisher":"John Wiley & Sons, Inc. ; Elsevier","dateIssuedKey":"2007"}],"id":{"issn":["1878-0261"],"eki":["531199800"],"zdb":["2322586-5"]},"name":{"displayForm":["Federation of European Biochemical Societies"]},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Molecular oncology","title":"Molecular oncology"}],"pubHistory":["1.2007 -"],"part":{"text":"12(2018), 8, Seite 1264-1285","volume":"12","extent":"22","year":"2018","pages":"1264-1285","issue":"8"},"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"A combined tissue-engineered/in silico signature tool patient stratification in lung cancerMolecular oncology","note":["Gesehen am 25.06.20"],"language":["eng"],"recId":"531199800"}],"origin":[{"dateIssuedDisp":"24 May 2018","dateIssuedKey":"2018"}],"id":{"eki":["1696293588"],"doi":["10.1002/1878-0261.12323"]},"name":{"displayForm":["Claudia Göttlich, Meik Kunz, Cornelia Zapp, Sarah L. Nietzer, Heike Walles, Thomas Dandekar and Gudrun Dandekar"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 28.04.2020"],"language":["eng"],"recId":"1696293588","title":[{"title_sort":"combined tissue-engineered/in silico signature tool patient stratification in lung cancer","title":"A combined tissue-engineered/in silico signature tool patient stratification in lung cancer"}],"person":[{"role":"aut","roleDisplay":"VerfasserIn","display":"Göttlich, Claudia","given":"Claudia","family":"Göttlich"},{"given":"Meik","family":"Kunz","role":"aut","roleDisplay":"VerfasserIn","display":"Kunz, Meik"},{"given":"Cornelia","family":"Zapp","role":"aut","display":"Zapp, Cornelia","roleDisplay":"VerfasserIn"},{"given":"Sarah L.","family":"Nietzer","role":"aut","display":"Nietzer, Sarah L.","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","display":"Walles, Heike","role":"aut","family":"Walles","given":"Heike"},{"role":"aut","display":"Dandekar, Thomas","roleDisplay":"VerfasserIn","given":"Thomas","family":"Dandekar"},{"roleDisplay":"VerfasserIn","display":"Dandekar, Gudrun","role":"aut","family":"Dandekar","given":"Gudrun"}]} 
SRT |a GOETTLICHCCOMBINEDTI2420